{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:49:24Z","timestamp":1773474564867,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"DOI":"10.7759\/cureus.105201","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:58:26Z","timestamp":1773471506000},"source":"Crossref","is-referenced-by-count":0,"title":["Combining Multiparametric Magnetic Resonance Imaging and Prostate-Specific Antigen Density in Selecting Patients for Prostate Biopsy"],"prefix":"10.7759","author":[{"given":"Goran","family":"Derimachkovski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgi","family":"Georgiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krastyo","family":"Draginov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Petkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Rumenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitar","family":"Stoilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yordan","family":"Tomov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasil","family":"Vasilev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krassimir","family":"Yanev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Prostate cancer burden in EU-27. (2021). Accessed. March 3, 2026: https:\/\/ecis.jrc.ec.europa.eu\/sites\/default\/files\/2023-12\/prostate_cancer_En-Nov_2021.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: an important clinical entity","volume":"11","author":"Salinas CA","year":"2014","unstructured":"Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014, 11:317-23. 10.1038\/nrurol.2014.91","journal-title":"Nat Rev Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.04.024","article-title":"Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial","volume":"62","author":"Vickers A","year":"2012","unstructured":"Vickers A, Bennette C, Steineck G, et al.. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol. 2012, 62:204-9. 10.1016\/j.eururo.2012.04.024","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.03.002","article-title":"Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies","volume":"66","author":"Pokorny MR","year":"2014","unstructured":"Pokorny MR, de Rooij M, Duncan E, Schr\u00f6der FH, Parkinson R, Barentsz JO, Thompson LC. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014, 66:22-9. 10.1016\/j.eururo.2014.03.002","journal-title":"Eur Urol"},{"key":"ref5","unstructured":"Prostate cancer. (2026). Accessed. March 3, 2026: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-017-0024-7","article-title":"Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer","volume":"21","author":"Nordstr\u00f6m T","year":"2018","unstructured":"Nordstr\u00f6m T, Akre O, Aly M, Gr\u00f6nberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018, 21:57-63. 10.1038\/s41391-017-0024-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.04.015","article-title":"Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy","volume":"105","author":"Jue JS","year":"2017","unstructured":"Jue JS, Barboza MP, Prakash NS, et al.. Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy. Urology. 2017, 105:123-8. 10.1016\/j.urology.2017.04.015","journal-title":"Urology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.03.130","article-title":"The value of PSA density in combination with PI-RADS\u2122 for the accuracy of prostate cancer prediction","volume":"198","author":"Distler FA","year":"2017","unstructured":"Distler FA, Radtke JP, Bonekamp D, et al.. The value of PSA density in combination with PI-RADS\u2122 for the accuracy of prostate cancer prediction. J Urol. 2017, 198:575-82. 10.1016\/j.juro.2017.03.130","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13619","article-title":"The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting","volume":"119","author":"Hansen NL","year":"2017","unstructured":"Hansen NL, Barrett T, Koo B, et al.. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. BJU Int. 2017, 119:724-30. 10.1111\/bju.13619","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13465","article-title":"Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy na\u00efve patients","volume":"119","author":"Washino S","year":"2017","unstructured":"Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy na\u00efve patients. BJU Int. 2017, 119:225-33. 10.1111\/bju.13465","journal-title":"BJU Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey B","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al.. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol. 2019, 76:340-51. 10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders GJ","year":"2020","unstructured":"van Leenders GJ, van der Kwast TH, Grignon DJ, et al.. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020, 44:e87-99. 10.1097\/PAS.0000000000001497","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.006","article-title":"The contemporary concept of significant versus insignificant prostate cancer","volume":"60","author":"Ploussard G","year":"2011","unstructured":"Ploussard G, Epstein JI, Montironi R, et al.. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011, 60:291-303. 10.1016\/j.eururo.2011.05.006","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12639","article-title":"Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies","volume":"115","author":"Rais-Bahrami S","year":"2015","unstructured":"Rais-Bahrami S, Siddiqui MM, Vourganti S, et al.. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015, 115:381-8. 10.1111\/bju.12639","journal-title":"BJU Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18008","article-title":"Risk stratification among men with Prostate Imaging Reporting and Data System version 2 category 3 transition zone lesions: is biopsy always necessary?","volume":"209","author":"Felker ER","year":"2017","unstructured":"Felker ER, Raman SS, Margolis DJ, et al.. Risk stratification among men with Prostate Imaging Reporting and Data System version 2 category 3 transition zone lesions: is biopsy always necessary?. AJR Am J Roentgenol. 2017, 209:1272-7. 10.2214\/AJR.17.18008","journal-title":"AJR Am J Roentgenol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan V","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al.. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018, 378:1767-77. 10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed HU","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al.. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017, 389:815-22. 10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson MC","year":"1992","unstructured":"Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992, 147:815-6. 10.1016\/s0022-5347(17)37393-7","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620628","article-title":"Diagnostic ability of dynamic contrast-enhanced magnetic resonance imaging for prostate cancer and clinically significant prostate cancer in equivocal lesions: a systematic review and meta-analysis","volume":"11","author":"Zeng J","year":"2021","unstructured":"Zeng J, Cheng Q, Zhang D, Fan M, Shi C, Luo L. Diagnostic ability of dynamic contrast-enhanced magnetic resonance imaging for prostate cancer and clinically significant prostate cancer in equivocal lesions: a systematic review and meta-analysis. Front Oncol. 2021, 11:620628. 10.3389\/fonc.2021.620628","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00872-6","article-title":"Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions","volume":"28","author":"Mjaess G","year":"2025","unstructured":"Mjaess G, Haddad L, Jabbour T, et al.. Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions. Prostate Cancer Prostatic Dis. 2025, 28:173-9. 10.1038\/s41391-024-00872-6","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10859-9","article-title":"Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate","volume":"12","author":"Boschheidgen M","year":"2022","unstructured":"Boschheidgen M, Schimm\u00f6ller L, Doerfler S, et al.. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. Sci Rep. 2022, 12:6746. 10.1038\/s41598-022-10859-9","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.09.001","article-title":"Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7-10 prostate cancer in biopsy-na\u00efve men","volume":"2","author":"Boesen L","year":"2019","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, et al.. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7-10 prostate cancer in biopsy-na\u00efve men. Eur Urol Oncol. 2019, 2:311-9. 10.1016\/j.euo.2018.09.001","journal-title":"Eur Urol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.008","article-title":"Prebiopsy improd biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer: an external validation study","volume":"3","author":"Knaapila J","year":"2020","unstructured":"Knaapila J, Jambor I, Perez IM, et al.. Prebiopsy improd biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer: an external validation study. Eur Urol Oncol. 2020, 3:648-56. 10.1016\/j.euo.2019.08.008","journal-title":"Eur Urol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.112","article-title":"Defining the threshold for significant versus insignificant prostate cancer","volume":"10","author":"Van der Kwast TH","year":"2013","unstructured":"Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol. 2013, 10:473-82. 10.1038\/nrurol.2013.112","journal-title":"Nat Rev Urol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson IM","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter. N Engl J Med. 2004, 350:2239-46. 10.1056\/NEJMoa031918","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13458","article-title":"Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012","volume":"119","author":"Danneman D","year":"2017","unstructured":"Danneman D, Drevin L, Delahunt B, et al.. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int. 2017, 119:50-6. 10.1111\/bju.13458","journal-title":"BJU Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.08.006","article-title":"Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature","volume":"52","author":"Scattoni V","year":"2007","unstructured":"Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007, 52:1309-22. 10.1016\/j.eururo.2007.08.006","journal-title":"Eur Urol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt151","article-title":"Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men","volume":"105","author":"Zlotta AR","year":"2013","unstructured":"Zlotta AR, Egawa S, Pushkar D, et al.. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013, 105:1050-8. 10.1093\/jnci\/djt151","journal-title":"J Natl Cancer Inst"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)","volume":"4","author":"Falagario UG","year":"2021","unstructured":"Falagario UG, Jambor I, Lantz A, et al.. Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). Eur Urol Oncol. 2021, 4:971-9. 10.1016\/j.euo.2020.08.014","journal-title":"Eur Urol Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.02.021","article-title":"Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer","volume":"73","author":"Venderink W","year":"2018","unstructured":"Venderink W, van Luijtelaar A, Bomers JG, et al.. Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer. Eur Urol. 2018, 73:353-60. 10.1016\/j.eururo.2017.02.021","journal-title":"Eur Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472965-combining-multiparametric-magnetic-resonance-imaging-and-prostate-specific-antigen-density-in-selecting-patients-for-prostate-biopsy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:58:27Z","timestamp":1773471507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472965-combining-multiparametric-magnetic-resonance-imaging-and-prostate-specific-antigen-density-in-selecting-patients-for-prostate-biopsy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.105201","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}